ECTRIMS Congress
ECTRIMS 2022 Congress Highlights:
Keep up to date with the latest advances in multiple sclerosis (MS) with our coverage of Merck Healthcare KGaA, Darmstadt, Germany-sponsored medical content from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 Congress, held in Amsterdam, the Netherlands. Learn more from experts in the field of MS as they discuss:
- Recent advances in understanding MS immune pathophysiology and implications for clinical practice
- The latest results from key studies in the MS field
- The use of immune reconstitution therapies for long-term MS management
- Benefits of the early-use of high-efficacy therapies in MS
ECTRIMS Symposium
Infiltration of peripheral immune cells into the central nervous system (CNS) of patients with MS and their interaction with resident cells; why, when and how we should target them. A symposium co-chaired by Professor Gavin Giovannoni and Professor Celia Oreja-Guevara.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
ECTRIMS ePosters
Watch this series of expert discussions on relapsing-multiple sclerosis (RMS), covering key data presented at ECTRIMS 2022. Learn more about:
- Efficacy, safety and quality of life (QoL) outcomes following treatment with high-efficacy disease modifying therapies (DMT)
- Post-approval safety profile updates for cladribine tablets in patients with highly active RMS
- The latest data reporting on treatment adherence for highly active RMS
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
Long-term MS management with immune reconstitution therapies
Be updated with the latest considerations, data, and expert opinions on the long-term management of multiple sclerosis (MS) with immune reconstitution therapies (IRT).
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
High-efficacy MS treatment: early compared to escalation approaches
Should patients be started on high-efficacy disease modifying therapies (DMT) as early as possible in their multiple sclerosis (MS) treatment pathway? MS experts Professor Gavin Giovannoni and Professor Jiwon Oh examine the arguments for and against early initiation.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
of interest
are looking at
saved
next event
Developed by EPG Health, for Medthority. This content has been developed in collaboration with Merck KGaA, Darmstadt, Germany. The materials shown in the webinar are intended for discussion purposes and must not be considered medical advice from a healthcare professional. EPG Health, received funding from Merck KGaA, Darmstadt, Germany in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. Any data on non-Merck KGaA, Darmstadt, Germany products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.